The patent covers protection of brain cells, as well as stimulation of brain repair, using ingredients in QuadraMune and variations of the ingredients.
The company has previously demonstrated synergy between the ingredients in this nutraceutical. This is the third patent being granted on QuadraMune, which is commercially available from numerous sources, including on Amazon.
The first patent covered the use of QuadraMune for immune modulation in cancer and COVID-192. The second covered prevention and treatment of COVID-193 by QuadraMune administration.
Previously the company has shown that QuadraMune can increase the ability of natural killer cells to kill target cells, which is an important part of the body's defense mechanisms to viruses and cancer. Interestingly, addition of the diabetes drug metformin increased activity of QuadraMune.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes